BIO
Biome Australia Limited
🇦🇺 ASX
🛍️ CONSUMER
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
+ 42.50%
Annual Growth
3 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
25
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Biome Australia Ltd. engages in the research, development, manufacture, and distribution of evidence-based products linking the gut and human health. The firm develops, licenses, commercializes and markets evidence-based live biotherapeutics (probiotics) and complementary medicines. The company develops, manufactures, and distributes evidence-based products linking the gut and human health through the Company owned brands, such as Activated Nutrients and Activated Probiotics. Activated Nutrients offers a range of completely organic, plant-based, all in-one nutritional products. Activated Probiotics offers a range of clinically backed precision probiotics. Activated Probiotics provides live biotherapeutic products clinically proven to help prevent and support the management of various health concerns, including low mood and sleep, bone health, iron malabsorption, mild eczema through randomized double-blind placebo-controlled trials. Activated Probiotics products include Biome Acne Probiotic, Biome Baby Probiotic, Biome Eczema Probiotic, and Biome Acne Probiotic.
📈 Performance
Price History
+142.50%
1M
1Y
All Time
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.48
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in BIO
25
📊 Total Capital Earnings
$7K
🔃 Average investment frequency
30 weeks
💵 Average investment amount
$1,409
⏰ Last time a customer invested in BIO
3 hours
BIO investor breakdown
💵 Income of investors
More than 200k
11%
150k - 200k
100k - 150k
50k - 100k
48%
Less than 50k
37%
👶 Age of investors
18 - 25
24%
26 - 34
20%
35 - 90
56%
🙋 Legal gender of investors
Female
52%
Male
48%
Pearlers who invest in BIO also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
8.32%
📊 Share price
$94.88 AUD
💸 FINANCIALS
🧱 MATERIALS
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
15.01%
📊 Share price
$129.51 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
19.83%
📊 Share price
$57.04 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
Telix Pharmaceuticals Limited.engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-15. The firm is focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. The company develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. The company operates a pipeline of theranostic radiopharmaceutical product candidates with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Its segments include commercial, product development, medical technologies, and manufacturing services. Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX101, TLX300, TLX66, TLX66-CDx, and TLX090, among others.
🙌 Performance (5Yr p.a)
367.38%
📊 Share price
$23.63 AUD
🧬 BIOTECHNOLOGY
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6698.35m in AUM and 201 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
🙌 Performance (5Yr p.a)
8.86%
📊 Share price
$128.01 AUD
🇦🇺 AUSTRALIA
⛳️ DIVERSIFIED
💸 FINANCIALS
📈 HIGH PRICE GROWTH
Want more shares? Try these...
